We have studied the effects of mivacurium after induction of anaesthesia with alfentanH-propofol in healthy adult oral surgical patients. Anaesthesia was maintained with nitrous oxide and 0.75% (end-tidal) shown that it has a shorter duration of action than currently approved non-depolarizing agents and may be suitable for providing neuromuscular block for procedures of brief duration when suxamethonium is not desired, and for maintenance of neuromuscular block by infusion.
SUMMARY

We have studied the effects of mivacurium after induction of anaesthesia with alfentanH-propofol in healthy adult oral surgical patients. Anaesthesia was maintained with nitrous oxide and 0.75% (end-tidal) enflurane in oxygen after nasotracheal intubation. Recordings were made of the rectified compound adductor pollicis electromyogram in response to train-of-four (TOF) ulnar nerve stimulation. First and fourth TOF responses were defined as 11 and 14. with 71 suppression referenced to pre-mivacurium 11 height (1c). Onset times (mean (SEM)
Mivacurium chloride (BW B1090U) is a new nondepolarizing neuromuscular blocking agent. Previous clinical trials in the United States [1] [2] [3] [4] [5] [6] [7] [8] [9] have shown that it has a shorter duration of action than currently approved non-depolarizing agents and may be suitable for providing neuromuscular block for procedures of brief duration when suxamethonium is not desired, and for maintenance of neuromuscular block by infusion.
We have assessed onset times and conditions at tracheal intubation after fast bolus administration of mivacurium. A slow bolus injection group was included also, as mivacurium may be associated with cutaneous flushing and arterial hypotension caused by systemic release of histamine [8] . Infusion requirements were ascertained under anaesthesia with nitrous oxide and enflurane, and the time for spontaneous recovery of neuromuscular function was compared with that achieved after neostigmine or edrophonium.
PATIENTS AND METHODS
The study was approved by the Committee on Safety of Medicines and the local Ethics Committee. Forty five patients requiring nasotracheal intubation for elective oral surgical procedures gave written informed consent. They were of physical status ASA I or II, and not taking antihistamines or medications known to affect neuromuscular function. Premedication 60-90 min before induction of anaesthesia consisted of oral atropine 1 mg and temazepam 20-30 mg. Electrocardiographic and non-invasive arterial pressure monitoring (Datascope Accutorr) commenced in the anaesthetic room. Adhesive, prejelled silver-silver chloride surface electrodes were positioned on the wrist and hand, and connected to a Datex Relaxograph in order to detect the evoked gated integrated rectified compound electromyographic (EMG) response of the adductor pollicis muscle to supramaximal trainof-four (TOF) ulnar nerve stimulation (0.1-ms square-wave stimuli at 2 Hz for 2 s; train frequency 0.05 Hz). The hand from which EMG recordings were obtained was immobilized with the thumb abducted, and the arm was wrapped in cotton wool to minimize heat loss. Palmar and core temperatures were monitored with skin and nasopharyngeal probes.
After i.v. induction of anaesthesia with alfentanil 0.5-1.0mg and propofol 2.0-2.5mg kg" 1 , a stable baseline EMG recording was obtained. Rectified EMG output from the Relaxograph was recorded continuously on a Gould 220 chart recorder for later analysis. The height of the first response (Tl) of the TOF at baseline was defined as the control response (Tc). Before tracheal intubation, anaesthesia was maintained with 66 % nitrous oxide in oxygen, and increments of alfentanil and propofol as clinically indicated. Mivacurium 2 mg ml" 1 was administered at least 2 min after the last increment of alfentanil or propofol.
Patients were studied in three groups. The first 18 patients (group A) were allocated randomly to receive an initial dose of mivacurium 0.15 mg kg" 1 (subgroup Al) or O^mgkg" 1 (subgroup A2) as a rapid, 5-s bolus via a peripheral vein, and trachea! intubation was attempted 2.5 min later. The next 18 patients (group B) were similarly allocated randomly to receive mivacurium 0.15 mg kg" 1 (subgroup Bl) or O^mgkg" 1 (subgroup B2) by rapid, 5-s bolus, but with tracheal intubation 2 min after the injection of mivacurium. The final nine patients (group C) received mivacurium 0.2 mg kg" 1 over 30 s, with tracheal intubation attempted 2 min later. Intubating conditions were graded on an interval scale from 1 = excellent to 4 = not possible, according to the observed state of relaxation of the vocal cords and the severity of coughing or passing the tracheal tube. After successful tracheal intubation, enflurane was added to the inspired gases to achieve an end-tidal concentration of 0.75% (Datex Normac) and ventilation was controlled to maintain an end-tidal partial pressure of carbon dioxide 4.4-5.4 kPa (Datex Normocap). Nasopharyngeal and palmar temperatures were maintained greater than 35 °C and 33 °C, respectively.
All patients received an infusion of mivacurium 0.5 mg ml" 1 in 5 % glucose to extend neuromuscular block for the duration of surgery. Infusions were commenced after EMG recovery from the initial bolus of mivacurium was evident (Tl/Tc > 5%). An initial infusion rate of 10 ug kg" 1 min" 1 was used in the first nine patients studied, but in subsequent patients this was modified to 8 ug kg" 1 min"
The rate was then adjusted by increments of 1 ug kg" 1 min" 1 at intervals of at least 3 min to achieve and maintain Tl/Tc in the range 1-10% (90-99% Tl suppression). Infusions were administered using a Ohmeda 9000 syringe pump and a dedicated i.v. cannula.
Towards the end of surgery the infusion was discontinued and group B patients allowed to recover spontaneously from the effects of mivacurium. Residual neuromuscular block was antagonized with neostigmine 40 ug kg" 1 and atropine 20 ug kg" 1 in group A patients, and with edrophonium 750 jig kg" 1 preceded by atropine 10 ug kg" 1 in group C patients. EMG monitoring was continued until the T4:T1 ratio (the ratio of the height of the 4th response (T4) of the TOF to Tl) reached at least 0.7. Anaesthesia was discontinued and, after spontaneous ventilation was established, the trachea was extubated. ' For each patient, the times from bolus injection to 90% and to maximal Tl suppression, Tl suppression at intubation, intubation scores and times for initial recovery of Tl/Tc to 5% and 10 % were noted. (All times were from completion of injection of mivacurium.) Changes in infusion rate, mean infusion rate and infusion duration were recorded. After infusions, Tl/Tc at antagonism (groups A and C) or at cessation of infusion (group B) was noted, and the time for recovery to T4:T1 ratios of 0.5 and 0.7 recorded. Patient data were analysed with one-way analysis of variance (ANOVA). Neuromuscular data were analysed using one-way ANOVA, Student-NewmanKeuls test, and Bonferroni t tests as appropriate. Chi square was used to analyse intubation scores. P < 0.05 was considered statistically significant.
Non-invasive cardiovascular monitoring was performed according to normal anaesthetic prac- tice. Clinical signs of histamine release, such as cutaneous flushing were documented. In addition, arterial pressure (AP) and heart rate (HR) were recorded immediately before and every 1 min for 10 min after the initial dose of mivacurium. Baseline AP and HR were denned as values immediately preceding administration of mivacurium. In order to avoid the compounding haemodynamic effects of tracheal intubation, analyses were made only of the maximum change in HR and mean arterial pressure (MAP) from baseline observed in the period after mivacurium but before tracheal intubation. Paired t tests and Fisher's Exact tests were used to analyse these changes and significance taken at P < 0.05.
RESULTS
Patient groups were comparable with respect to weight, age, height and total doses of propofol and alfentanil received before the initial attempt at tracheal intubation (table I) . There were no significant differences between patients who received initial 5-s boluses of mivacurium 0.15 mg kg" 1 (subgroups Al and Bl) or O^mgkg" 1 (subgroups A2 and B2).
There were no significant differences in onset and early recovery data between subgroups that received identical initial mivacurium doses over 5 s; such data were analysed in combination and are summarized in table II. Mean onset times (from end of injection) to 90 % and to maximal Tl suppression after mivacurium 0.15 mg kg" 1 were slower than those after 0.2 mg kg" 1 , although the difference in times to 90% suppression between the two doses when administered over 5 s was not statistically significant. Tl suppression of 100% was produced in all but two patients; one reached 97 % suppression after a dose of 0.15 mg kg" 1 , and another achieved maximal Tl suppression of only 90 % after mivacurium 0.2 mg kg" 1 administered over 5 s.
Data from three patients in whom oral tracheal intubation was performed (n = 1) or unexpectedly difficult insertion of the tracheal tube through the nasal passage was encountered (n = 2) were ex- table III . Intubating conditions were generally good to excellent 2 or 2.5 min after mivacurium 0.15 mg kg" 1 ; whilst in two patients the trachea could not be intubated at 2.5 min, all patients given this dose in whom tracheal intubation was attempted at 2 min displayed at least good conditions. The two patients presented early in the study, and inexperience may have been partly responsible for the failures. Mean Tl suppression at 2 min after mivacurium 0.15 mg kg" 1 was 72 %-less than that at 2.5 min in comparable patients given the same dose (88 %). Mean Tl suppression was greater in patients given mivacurium 0.2 mg kg" 1 compared with those who received the lesser dose, but no significant benefit in terms of superior intubating scores was demonstrated. Slowing the rate of injection of a 0.2-mg kg" 1 dose did not influence conditions at 2 min, although it should be stressed that timings were taken from completion of injection.
Mean times from administration of the mivacurium bolus to 5% and 10% Tl recovery were 11-13 min and 13-15 min, respectively, with no significant relation to dose or to initial speed of administration (table II) . One patient did not achieve sufficient Tl suppression to be included in these recovery times, and in another three patients the mivacurium infusion was started after recovery to Tl of 5%, but before recovery to 10%.
There was no discernible bolus dose or group related differences in infusion data, which were pooled, therefore, for all patients (table IV) . Over the first 15 min, regular changes in infusion rates were generally necessary. After this time, infusion rates usually remained stable ( fig. 1 ), although 1-ug kg" 1 min" 1 changes in infusion rate to correct drift outside the target Tl/Tc range occasionally resulted in temporary overcorrection. Mean infusion rate for all patients in the period after the 15-min stabilization was 6.6 ug kg" 1 min" 1 (range 2.3-12.9 ug kg" 1 min" 1 ). There was a negative trend between individual times from initial bolus administration of mivacurium to 5% Tl/Tc recovery and post-15 min infusion rates (fig. 2) ; whilst tests for equality of slopes of regression lines failed to demonstrate significant differences related to size of initial dose, pooled regression analyses were felt to be inappropriate.
On termination of infusions, mean Tl/Tc, and Tl/Tc ranges at the time of administration of anticholinesterase were similar in group A and group C patients, and comparable to those at termination of infusion in group B patients in whom spontaneous recovery was allowed (table  V) . Occasional patients in all three groups were outside the 1-10% Tl/Tc range at the time of termination of infusion, for the reason mentioned above. Spontaneous recovery was fairly rapid and often evident to a small degree before administration of anticholinesterase. Compared with spontaneous recovery, both anticholinesterases significantly increased the speed of recovery. A T4:T1 ratio of 0.7, but not 0.5, was reached significantly more rapidly in patients given edrophonium compared with those who received neostigmine. No patient manifested signs of muscle weakness in the recovery area when assessed by 5-s head lift and hand grip. Mean maximum changes in MAP from baseline observed after initial injection of mivacurium but before tracheal intubation were decreases of 0.9 (SD 7.6), 6.3 (8.5) and 5.3 (10.5) mm Hg in patients who received mivacurium 0.15, 0.2 (rapid), and 0.2 (slow) mg kg" 1 , respectively. Corresponding mean maximum increases in HR were 1.7 (SD 5.9), 4.7 (12.7) and 6.9 (12.6) beat min- 1 . These changes bore no significant relation to dose or to speed of administration and were not significant deviations from mean baseline values. Decreases in MAP > 20% of baseline were observed in one of 18 patients (6%) who received a rapid 0.15-mg kg" 1 bolus, compared with five of 18 (28%) and three of nine (33%) patients after a rapid or slow 0.2-mg kg" 1 dose, respectively (P > 0.05). There was no difference relating to dose or to speed of administration in the incidence of flushing (five of 18 patients after mivacurium 0.15 mg kg" 1 ; six of 18 after rapid O^mgkg" 1 ; three of nine after 0.2 mg kg" 1 over 30 s). No other untoward perioperative events attributable to mivacurium were observed. ) were selected as appropriate to facilitate tracheal intubation at 2-2.5 min, and on the basis of published work approximate to 2.0 and 2.5 x ED B6 estimates during opioid anaesthesia [7] . Larger doses may (with priming) produce favourable intubating conditions at 90 or even 60 s [6] , but may not be clinically useful because of untoward cardiovascular effects which are dosedependent at doses in excess of 0.15 mg kg" 1 [3, 8] . Enflurane is reported to potentiate the neuromuscular effects of mivacurium [4] and its administration was delayed until after tracheal intubation and the development of 90% Tl suppression.
Thiopentone was the induction agent used in previous studies, whereas our patients received propofol. Our results on onset of block are similar to those reported previously during opioid anaesthesia, with no evidence to suggest that a single bolus dose of propofol alters the action of mivacurium. Whilst it is recognized that ease of tracheal intubation depends on other factors in addition to the degree of neuromuscular block, intubating conditions at 2 min were adequate in most patients after mivacurium 0.15 mg kg" 1 , with no significant benefit in waiting a further 30 s or in increasing the dose to 0.2 mg kg" 1 . It may be inappropriate to compare these findings with those of other workers, as tracheal intubation was performed via the nasal route. Tl recovery to 10% of Tc was more than twice as rapid as that reported after vecuronium during enflurane anaesthesia [10] , and about twice that after an intubating dose of suxamethonium [2, 3] . It should be stressed, however, that mivacurium was not administered initially during stable enflurane anaesthesia in this study. We were unable to demonstrate any differences in early recovery times between the two doses, which is not very surprising in view of their similarity and the relatively small number of patients studied.
After an initial period of stabilization, infusions of mivacurium provided controllable neuromuscular block for up to 2 h. An initial rate of 10 ug kg" 1 min" 1 , advocated previously during opioid anaesthesia [1], proved too great for our patients during enflurane anaesthesia and a lesser initial rate was thus adopted. Our mean infusion rate of 6.6 ug kg" 1 min" 1 is almost identical to that during enflurane anaesthesia reported by Caldwell and colleagues [3] . However, as with atracurium and vecuronium [1, 3, 11] , we observed a marked (more than five-fold) variation in individual infusion rates. As recovery from mivacurium is largely a result of breakdown by plasma pseudocholinesterase [5] , part of this variation may be a result of interpatient differences in activity of this enzyme [1, 7] . Our results may also show that individual sensitivity to mivacurium in terms of longer recovery time after bolus doses may be expressed also as lower infusion requirements, as shown previously [9] , but we would hesitate to suggest that recovery time may broadly predict stable infusion rate outside our prevailing study conditions.
When competitive neuromuscular blocking drugs are used, attainment of a T4: Tl ratio of 0.7 is widely believed to equate with clinically adequate recovery [12, 13] , although some workers argue that even further recovery is necessary to ensure airway protection [14] , especially when using EMG monitoring [15] . We do not yet know if these data are applicable to mivacurium, and elected to use an EMG T4:T1 of 0.7 as the end-point of our neuromuscular monitoring. Spontaneous recovery to a T4:T1 of 0.7 took 17 min, approximately 50% as long as that shown earlier for atracurium under comparable conditions [11] . Whilst edrophonium was shown to be superior to neostigmine in accelerating recovery, no work has yet been performed on the relative potencies of these agents when antagonizing mivacurium-induced block, and the doses used may not have been strictly comparable. No patient demonstrated evidence of inadequate muscle power in the period after attainment of an EMG T4:T1 of 0.7, but subtle alterations in ventilatory mechanics were not evaluated.
In contrast with previous findings after thiopentone-opioid induction [8] , we failed to demonstrate any significant differences in AP and HR changes in the period immediately after rapid injection between the two doses used. This may possibly have been the result of our use of propofol at induction, or the use of atropine in premedication. We suggest, however, that a 30% incidence of decreases in MAP ^ 20 % after mivacurium 0.2 mg kg" 1 , even with slow injection, may be clinically unacceptable. Cutaneous flushing was noted in approximately 30% of patients, and there was no relationship with dose or speed of injection. In view of the similarity in efficacy between 0.15-and 0.2-mg kg" 1 doses and the reported haemodynamic effects of greater doses, we conclude that there seems little clinical justification in the use of a dose of mivacurium exceeding 0.15 mg kg" 1 .
